The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HER3 expression status following systemic chemotherapy treatment in biliary tract cancers.
 
Mariko Nishioka
No Relationships to Disclose
 
Chigusa Morizane
Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - MSD K.K.; SERVIER; Yakult Honsha
Research Funding - AstraZeneca (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Mao Okada
No Relationships to Disclose
 
Tomoyuki Satake
No Relationships to Disclose
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Satoshi Nara
No Relationships to Disclose
 
Tomoya Kakegawa
Employment - Daiichi Sankyo RD Novare
 
Maki Kobayashi
Employment - Daiichi Sankyo RD Novare
 
Kumiko Koyama
Employment - Daiichi Sankyo Co., Ltd.
 
Minoru Esaki
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst)